3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Thrombocytopenia
6
Lymphoma, Non-Hodgkin
3
Purpura, Thrombocytopenic, Idiopathic
2
Purpura, Thrombocytopenic
2
Neoplasms
2
Multiple Myeloma
2
Hodgkin Disease
2
Solid Tumor
1
Pancreatic Neoplasms
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Bevacizumab
112
Fluorouracil
98
Oxaliplatin
96
Leucovorin
96
Irinotecan
86
Capecitabine
73
Cetuximab
64
Panitumumab
42
pembrolizumab
38
regorafenib
28
Nivolumab
23
IFL protocol
22
Folfox protocol
21
trifluridine tipiracil drug combination
14
Radiotherapy
13
durvalumab
11
Gemcitabine
10
Celecoxib
10
tremelimumab
7
binimetinib
7
aflibercept
7
Drug Therapy
7
Disulfides
7
Cyclophosphamide
7
Trifluridine
6
Trastuzumab
6
Sunitinib
6
Paclitaxel
6
Immunoglobulin G
6
Colonoscopy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Colorectal Neoplasms
×
romiplostim
×
Clear all
NCT03362177
2026-02-11
RECITE
Amgen
Phase 3
Completed
165 enrolled
22 charts